Prime Medicine wins FDA IND clearance for PM647 in AATD
Prime Medicine has secured FDA clearance of its Investigational New Drug application for PM647, an in vivo Prime Editor designed to treat alpha-1 antitrypsin deficiency (AATD). The clearance, announced on 24 September 2026, allows the Nasdaq-listed company to initiate clinical study in the United States, where an estimated 100,000 individuals carry the PiZZ genotype that PM647 targets.
AATD is caused by mutations in the SERPINA1 gene, most commonly the E342K variant known as Pi*Z. The condition drives progressive lung damage through insufficient functional AAT protein and, separately, liver disease caused by the accumulation of the misfolded mutant protein. No approved therapy currently addresses both manifestations at the genetic level; existing options, including augmentation therapy with infused AAT protein, manage symptoms rather than correct the underlying defect.
The programme
PM647 is designed to correct the E342K mutation directly, restoring production of functional M-AAT. In fully humanised mouse models, a single infusion of PM647 achieved editing efficiency that returned corrected M-AAT protein into the healthy human range at clinically relevant doses. The candidate uses the same liver-directed lipid nanoparticle delivery system as PM577a, Prime Medicine's investigational programme for Wilson disease, which itself received IND clearance earlier in 2026.
The planned Phase 1/2 trial is a global, single-arm, open-label, first-in-human study evaluating safety, tolerability and preliminary efficacy at ascending doses. Initial enrolment will focus on adults with lung-only disease; once tolerability is established, a second cohort will open for patients with significant liver involvement. The company said it expects to report initial clinical data in 2027.
Chief executive Allan Reine described the clearance as evidence of the modularity of Prime Medicine's platform. "By correcting the underlying mutation and restoring production of fully functional AAT, PM647 may simultaneously address both lung and liver manifestations of AATD," he said.
Market and competitive context
The AATD therapeutic landscape is undergoing a generational shift. Augmentation therapy, delivered intravenously on a weekly or biweekly basis, remains standard of care for lung disease but has no effect on the liver phenotype and does not alter disease progression. Several companies have pursued gene therapy approaches using adeno-associated virus vectors, though durability and immunogenicity questions have tempered enthusiasm for traditional AAV-based strategies in liver-targeted indications.
Prime Editing occupies a distinct position in the editing hierarchy. Unlike base editing, which is limited to transition mutations, or standard CRISPR-Cas9, which typically introduces insertions or deletions, Prime Editing is designed to install precise substitutions with reduced off-target activity. The E342K correction in SERPINA1 is a point-mutation repair well suited to the technology's strengths, which may give PM647 a differentiated profile if clinical safety and editing efficiency data hold in humans.
The broader competitive field includes programmes from companies exploring RNA interference and small-molecule approaches to reduce mutant protein accumulation in the liver. Prime Medicine's ability to demonstrate durable editing in human liver tissue, along with a clean safety profile in the ascending-dose cohorts, will be the pivotal question heading into 2027 readouts. A successful first-in-human dataset would also support the company's wider liver franchise, including PM577a, by validating the shared LNP delivery platform across multiple indications.